Product Description
A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/mogamulizumab)
Mechanisms of Action: CCR4 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Arab Emirates | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Kyowa Hakko Kirin
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: France, Italy, Japan, Spain, United Kingdom, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 2: Adult T-Cell Leukemia-Lymphoma|Mycosis Fungoides|Sezary Syndrome|T-Cell Cutaneous Lymphoma|T-Cell Lymphoma|T-Cell Peripheral Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05996185 | P2 |
Recruiting |
T-Cell Peripheral Lymphoma |
2026-11-01 |
|
| PLIGHT | P1 |
Recruiting |
Mycosis Fungoides |
2026-09-01 |
|
| IRB-300006649 (UAB2109) | P1 |
Recruiting |
Mycosis Fungoides|T-Cell Cutaneous Lymphoma|T-Cell Peripheral Lymphoma |
2026-04-30 |
|
| UMCC 2022.116 | P2 |
Recruiting |
T-Cell Cutaneous Lymphoma|Sezary Syndrome|Mycosis Fungoides|T-Cell Peripheral Lymphoma |
2025-12-01 |